Erlotiniblet and metastases to central nervous system Patient Reports February 09, 2012

Erlotiniblet Side Effects Report #5767224-2
Erlotiniblet side effect was reported by a Health Professional from UNITED STATES on June 11, 2008. Male patient, 61 years of age, weighting 172.0 lb, was diagnosed with non-small cell lung cancer and was treated with Erlotiniblet. After drug was administered, patient experienced the following side effects: confusional state, disease progression, metastases to central nervous system. Erlotiniblet dosage: 150 MG, QD ORAL. During the same period patient was treated with FULVESTRANT. Patient was hospitalized. Patient recovered.